Overview

* IRadimed ( IRMD ) Q3 revenue grows 16% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 rises 9% yr/yr, reflecting operational strength

* Company raises full-year 2025 revenue and EPS guidance

Outlook

* IRadimed ( IRMD ) raises full-year 2025 revenue guidance to $82.5 mln to $83.5 mln

* Company expects Q4 2025 revenue of $21.4 mln to $22.4 mln

* IRadimed ( IRMD ) anticipates full-year 2025 GAAP EPS of $1.68 to $1.72

Result Drivers

* RECORD REVENUE - Co reports record Q3 revenue of $21.2 mln, a 16% increase yr/yr, driven by strong demand for MRI-compatible devices

* FACILITY TRANSITION - Co experienced transitional inefficiencies moving to new Orlando facility but maintained 78% gross margin

* PRODUCT BACKLOG - Co reports all-time high backlog for pump and monitor products, positioning for future demand

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $21.20 $20.49

Revenue mln mln (2

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for IRadimed Corp ( IRMD ) is $82.50, about 6.9% above its October 31 closing price of $76.81

* The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 31 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)